Monitor for FDA acceptance of VY1706 IND in late Q2 2026—clearance would de-risk clinical entry and could drive the stock. Also watch for potential partnership or licensing activity given positive TRACER preclinical data.
Price Chart
Executive Summary
Voyager Therapeutics presented positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheimer's disease, at ASGCT 2026. VY1706 was well tolerated and reduced tau protein up to 64% in NHP brain regions. The IND application is on track for Q2 2026, with first-in-human dosing expected in H2 2026. This is a significant pipeline milestone, but the stock's historical reaction to positive news has been muted, suggesting tempered near-term upside.
Key Facts
- VY1706 IND on track for Q2 2026; clinical entry expected H2 2026
- 3-month GLP tox data: no adverse findings up to 5E13 vg/kg
- Tau protein reduction up to 64% in key brain regions (NHP, 13 weeks)
- TRACER platform capsids showed 25-30X muscle expression over AAV9 in NHPs
- Stealth capsid evades pre-existing neutralizing antibodies while retaining muscle tropism
Financial Impact
Not specified
Risk Factors
- Preclinical data may not translate to human efficacy
- IND clearance not guaranteed; FDA could place clinical hold
- Competition from other tau-targeting therapies (e.g., antisense, antibodies)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293787 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.02 | awaiting T+60 | — | $1.75 (−13.12%) |
Jul 13, 2026 15w ago | 8-K | $3.24 $2.46 | ▼ −24.07% | ▼ −28.07% | $1.75 (−45.83%) |
Jun 1, 2026 21w ago | 8-K | $3.79 $3.48 | ▼ −8.18% | ▼ −9.41% | $1.75 (−53.69%) |
May 13, 2026 23w ago | Press Release | $4.15 $3.27 | ▼ −21.20% | ▼ −25.64% | $1.75 (−57.71%) |
May 7, 2026 24w ago | Press Release | $4.05 $3.13 | ▼ −22.84% | ▼ −27.68% | $1.75 (−56.67%) |
Apr 27, 2026 26w ago | Press Release | $3.77 $3.09 | ▼ −18.04% | ▼ −22.03% | $1.75 (−53.45%) |
Apr 21, 2026 26w ago | 8-K | $4.14 $3.17 | ▼ −23.43% | ▼ −28.21% | $1.75 (−57.61%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.75 (+53.57%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.75 (+53.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers